We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are four stocks that are likely to beat earnings for the week of November 28th:
Supernus Pharmaceuticals, Inc. (SUPN - Free Report) : This specialty pharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 15.4% over the last 30 days.
The company is expected to report its earnings results for the quarter ending September on Nov 29 and has an Earnings ESP of +30.77%. This Zacks Rank #2 (Buy) has delivered positive earnings surprises in all of the trailing four quarters with an average beat of more than 100%.
Windtree Therapeutics, Inc. (WINT - Free Report) : This clinical-stage biotechnology company has witnessed the Zacks Consensus Estimate for its current year earnings improving 5.5% over the last 30 days.
The company is expected to report its earnings results for the quarter ending September on Dec 1 and has an earnings ESP of +22.70%. This Zacks Rank #2 company has also delivered positive earnings surprises 21.3% in the last quarter.
Virgin America Inc. : This scheduled air travel services provider has witnessed the Zacks Consensus Estimate for its current year earnings gaining 3.4% over the last 30 days.
The company is expected to report its earnings results for the quarter ending September on Dec 1 and has an earnings ESP of +17.82%. This Zacks Rank #3 (Hold) company has delivered positive earnings surprises in three out of four trailing quarter.
Golar LNG Ltd. (GLNG - Free Report) : This midstream liquefied natural gas (LNG) company has witnessed the Zacks Consensus Estimate for its current year earnings rising 1% over the last 30 days.
The company is expected to report its earnings results for the quarter ending September on Nov 30 and has an earnings ESP of +7.14%. This Zacks Rank #3 has delivered average positive earnings surprise of 0.9% in the trailing four quarters.
Our trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Ranked Income Stocks to Buy for November 28th
Here are four stocks that are likely to beat earnings for the week of November 28th:
Supernus Pharmaceuticals, Inc. (SUPN - Free Report) : This specialty pharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 15.4% over the last 30 days.
SUPERNUS PHARMA Price and Consensus
SUPERNUS PHARMA Price and Consensus | SUPERNUS PHARMA Quote
The company is expected to report its earnings results for the quarter ending September on Nov 29 and has an Earnings ESP of +30.77%. This Zacks Rank #2 (Buy) has delivered positive earnings surprises in all of the trailing four quarters with an average beat of more than 100%.
SUPERNUS PHARMA Price and EPS Surprise
SUPERNUS PHARMA Price and EPS Surprise | SUPERNUS PHARMA Quote
Windtree Therapeutics, Inc. (WINT - Free Report) : This clinical-stage biotechnology company has witnessed the Zacks Consensus Estimate for its current year earnings improving 5.5% over the last 30 days.
WINDTREE THERAP Price and Consensus
WINDTREE THERAP Price and Consensus | WINDTREE THERAP Quote
The company is expected to report its earnings results for the quarter ending September on Dec 1 and has an earnings ESP of +22.70%. This Zacks Rank #2 company has also delivered positive earnings surprises 21.3% in the last quarter.
WINDTREE THERAP Price and EPS Surprise
WINDTREE THERAP Price and EPS Surprise | WINDTREE THERAP Quote
Virgin America Inc. : This scheduled air travel services provider has witnessed the Zacks Consensus Estimate for its current year earnings gaining 3.4% over the last 30 days.
VIRGIN AMERICA Price and Consensus
VIRGIN AMERICA Price and Consensus | VIRGIN AMERICA Quote
The company is expected to report its earnings results for the quarter ending September on Dec 1 and has an earnings ESP of +17.82%. This Zacks Rank #3 (Hold) company has delivered positive earnings surprises in three out of four trailing quarter.
VIRGIN AMERICA Price and EPS Surprise
VIRGIN AMERICA Price and EPS Surprise | VIRGIN AMERICA Quote
Golar LNG Ltd. (GLNG - Free Report) : This midstream liquefied natural gas (LNG) company has witnessed the Zacks Consensus Estimate for its current year earnings rising 1% over the last 30 days.
GOLAR LNG LTD Price and Consensus
GOLAR LNG LTD Price and Consensus | GOLAR LNG LTD Quote
The company is expected to report its earnings results for the quarter ending September on Nov 30 and has an earnings ESP of +7.14%. This Zacks Rank #3 has delivered average positive earnings surprise of 0.9% in the trailing four quarters.
GOLAR LNG LTD Price and EPS Surprise
GOLAR LNG LTD Price and EPS Surprise | GOLAR LNG LTD Quote
See the full list of top ranked stocks here.
Learn more about Earnings ESP and how you can make it a part of your investing strategy here.
Now See All Our Private Trades
Our trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>